Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/10/16 | Current report filing |
|
13 | ||
| 10/20/16 | Confidential treatment order |
|
1 | ||
| 10/05/16 | Current report filing |
|
30 | ||
| 09/23/16 | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
6 | ||
| 09/22/16 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 09/21/16 | Current report filing |
|
6 | ||
| 09/16/16 | Prospectus filed pursuant to Rule 424(b)(5) |
|
78 | ||
| 09/16/16 | Prospectus filed pursuant to Rule 424(b)(5) |
|
66 | ||
| 09/16/16 | Current report filing |
|
51 | ||
| 09/15/16 | Prospectus filed pursuant to Rule 424(b)(5) |
|
78 |